Mustang Bio Inc (NASDAQ:MBIO) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as $4.92 and last traded at $4.92, with a volume of 709 shares changing hands. The stock had previously closed at $5.21.
Several research analysts have recently commented on MBIO shares. Zacks Investment Research raised shares of Mustang Bio from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a report on Saturday, August 18th. ValuEngine lowered shares of Mustang Bio from a “hold” rating to a “sell” rating in a report on Thursday, August 23rd.
The firm has a market cap of $162.21 million, a P/E ratio of -6.65 and a beta of 0.26.
Mustang Bio (NASDAQ:MBIO) last posted its quarterly earnings results on Monday, August 13th. The company reported ($0.19) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.06. Analysts predict that Mustang Bio Inc will post -0.84 EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of MBIO. Northern Trust Corp boosted its stake in Mustang Bio by 76.7% during the 1st quarter. Northern Trust Corp now owns 28,364 shares of the company’s stock valued at $310,000 after purchasing an additional 12,316 shares during the period. BlackRock Inc. boosted its stake in Mustang Bio by 904.5% during the 1st quarter. BlackRock Inc. now owns 21,646 shares of the company’s stock valued at $237,000 after purchasing an additional 19,491 shares during the period. A.R.T. Advisors LLC acquired a new position in Mustang Bio during the 1st quarter valued at about $186,000. Element Capital Management LLC acquired a new position in Mustang Bio during the 1st quarter valued at about $135,000. Finally, Millennium Management LLC boosted its stake in Mustang Bio by 271.7% during the 1st quarter. Millennium Management LLC now owns 101,029 shares of the company’s stock valued at $1,105,000 after purchasing an additional 73,850 shares during the period. 9.27% of the stock is owned by hedge funds and other institutional investors.
Mustang Bio Company Profile (NASDAQ:MBIO)
Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma.
Featured Article: What are trading strategies for the 52-week high/low?